InvestorLens

AMPH — AMPHASTAR PHARMACEUTICALS IN

Health Care

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying AMPH?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 4 buying vs 0 selling last quarter
72
Macro Tailwind
Macro conditions are mixed for this sector
58
Why? — Evidence & Confidence ▾

Of 4 tracked investors who changed their AMPH position last quarter, 4 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 58/100 in a Squeeze regime).

Supporting evidence
  • +4 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin, Steve Cohen, …)
  • +4 tracked investors reported holding AMPH at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for Health Caresource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About AMPHASTAR PHARMACEUTICALS IN (AMPH)

AMPHASTAR PHARMACEUTICALS IN (AMPH) appears in the most recent 13F filings of 4 tracked institutional investors. AMPHASTAR PHARMACEUTICALS IN is classified in the Health Care sector. The largest disclosed position is held by Howard Marks (Oaktree Capital Management), valued at $40M. Across recent filings, tracked investors recorded 9 new positions, 4 increased, 10 reduced, and 5 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in AMPH

46
/100
Mixed Activity
Added / Increased13
Reduced10
Exited5
BearishBullish
Crowded Trade Score™

How many top investors track AMPH

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

AMPH Ownership Composition

How AMPHASTAR PHARMACEUTICALS IN is held across tracked investor types, based on reported 13F positions.

Dominant Type
Value & Distressed
53% of tracked value
Institutions
4
tracked investors
Total Reported
$70.1M
combined 13F value
Types2
  • Value & Distressed53.1%
  • Multi-Strategy / Quant46.9%
Value & Distressed(1)
53.1%
Multi-Strategy / Quant(3)
46.9%

Tracked investors currently reporting AMPH

1 tracked investor has since exited this position — listed separately below.

  • Howard MarksJun 30, 2026
    Oaktree Capital Management
    Shares
    40.9M
    Value
    $37.2M
    % Portfolio
    0.52%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    34M
    Value
    $31M
    % Portfolio
    0.01%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    37.6K
    Value
    $759.4K
    % Portfolio
    0.00%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    55K
    Value
    $1.1M
    % Portfolio
    0.00%

Previously held AMPH

These investors reported AMPH in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Paul Tudor JonesTudor Investment Corp12.9K$296.6KJun 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold AMPH?
4 tracked institutional investors disclosed a position in AMPH (AMPHASTAR PHARMACEUTICALS IN) in their most recent 13F filing.
Who is the largest institutional holder of AMPH?
Howard Marks, Oaktree Capital Management, holds the largest disclosed position in AMPH, valued at $40M.
Did institutional ownership of AMPH increase or decrease?
Across recent 13F filings, tracked investors recorded 9 new positions, 4 increased, 10 reduced, and 5 fully exited AMPH.
What sector is AMPH in?
AMPHASTAR PHARMACEUTICALS IN is classified in the Health Care GICS sector.
Where does this AMPH ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.